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Figure 2. The position of liquid/liquid interface in a glass capillary milifluidic 
devices at the orifice size of 60 µm. (THF = tetrathydrofuran). 
Materials Composition 
Aqueous 
phase 
1. Mili-Q- 
    water 
2. PVP 
1. 0.99 (wt/wt) % 
2. 0.02 (wt/wt)% 
Organic 
phase 
 
1. THF 
2. PCL 
3. PCM 
1. 20 ml 
2. 6 mg/ml 
3. 70 (wt/wt) %   
    of polymer 
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Figure 1.  Functional nanoparticles administration route. 
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Functional pharmaceuticals nanoparticles are 
solid carriers with a mean size of less than 1 µm, 
which are capable to dissolve, entrap, 
encapsulate or attach active ingredients (drug) to 
its nanoparticle matrix [1,2]. In this study, a new 
approach for the formation of acetaminophen 
(PCM) encapsulated poly(ɛ-caprolactone) (PCL) 
nanoparticles with controllable size dependent 
has been performed in a glass capillary milifluidic 
device by nanoprecipitation(“diffusion-stranding”) 
method.  
This work was financially supported by the Ministry of Higher 
Education of Malaysia.  
1. To investigate the optimum conditions for the formation 
of PCM loaded nanoparticles by nanoprecipitation 
method using glass capillary milifluidic device. 
2. To characterise the properties of encapsulated 
nanoparticles based on its microscopic morphology, 
size, encapsulation efficiency, drug loading and in vitro 
drug release. 
          References: [1] Legrand, P. et al. (2007). Int. J. Pharm. 344, 33–43. [2]. Konno & Taylor (2008). Pharm. Res. 25, 969-978. 
The experiment was performed at different;  
(i) milifluidic device orifice size, (ii) flowrate ratio, 
(iii) PCL concentration, (v) PCM concentration 
and (vi) surfactant concentration.    
Figure 5.  Real diagram for 
experimental set-up. Figure 4.  Sample collections at different Qaq/Qor values  
and constant Qaq = 5 ml/h. 
Figure 3.  Schematic diagram for experimental set-up. 
Figure 8. Differential scanning calorimetry (DSC) 
thermograms. 
Figure 9. X-ray diffractometry (XRD) peaks. 
Inverted microscope 
High-speed camera 
Image  
acquisition 
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Table 1.  Optimum conditions for the 
formation of functional pharmaceutical 
nanoparticles. 
* Note : PVP = polyvinyl pyrrolidone Figure 6. Particle mean size, Zave of PCL nanoparticles 
at different flowrate ratio and orifice size.  
(Conc.Organic phase = 1 mg/ml.)  
Figure 7. FEG-SEM images of; (a-b) blank poly(ɛ-caprolactone (PCL) and  (c-d) acetaminophen 
encapsulated PCL nanoparticles at various magnifications. 
(a) 
(d) (c) 
(b) 
Acetaminophen (PCM) encapsulated nanoparticles are 
potentially can be considered as a promising functional 
pharmaceutical carrier produced by a new approach of glass 
capillary milifluidic device. 
Figure 10. In vitro release profile of PCM encapsulated 
nanoparticles in two different release mediums.   
The highlight results: 
 
The mean size of encapsulated 
nanoparticles exhibited less than 500 nm 
with 52 % encapsulation efficiency and 22 % 
of drug loading. 
PCM encapsulated nanoparticles showed 
significantly encouraging results in FEG-
SEM, DSC and XRD analyses. 
In vitro release studies showed that PCL 
nanoparticles could successfully control the 
release of acetaminophen up to more than 
120 h.  
